|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.86 EUR | +22.48% |
|
+27.83% | +145.19% |
| 07-03 | Genfit soars on news of U.S. reimbursement for a product | |
| 07-03 | Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement | MT |
Company Valuation: GENFIT
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 154.9 | 214.6 | 197 | 176 | 176.3 | 670.3 | 670.3 | - |
| Change | - | 38.52% | -8.19% | -10.69% | 0.17% | 280.28% | 0% | - |
| Enterprise Value (EV) 1 | 169.6 | 30.1 | 131.8 | 168.4 | 156.6 | 166.7 | 623.5 | 613.5 |
| Change | - | -82.25% | 337.75% | 27.79% | -6.98% | 6.41% | 1.28% | -1.6% |
| P/E | -1.54x | 3.51x | -8.27x | -6.1x | 118x | -3.06x | 70.5x | 89x |
| PBR | -9.5x | 2.55x | - | 2.59x | 2.54x | 7.28x | 8.52x | 10.2x |
| PEG | - | -0x | 0x | -0.3x | -1x | 0x | -0x | -4.3x |
| Capitalization / Revenue | 20x | 2.51x | 7.42x | 4.61x | 2.48x | 3.69x | 7.04x | 5.62x |
| EV / Revenue | 21.9x | 0.35x | 4.96x | 4.41x | 2.21x | 2.34x | 6.55x | 5.14x |
| EV / EBITDA | -2.29x | 0.87x | -5.18x | -6.75x | 31.3x | -3.22x | 22.2x | 10.1x |
| EV / EBIT | -2.19x | 0.95x | -4.83x | -6.33x | 47.7x | -37x | 21.3x | 10.1x |
| EV / FCF | -1.74x | 0.3x | - | -3.02x | 10.7x | -6.04x | -52x | 12,269x |
| FCF Yield | -57.4% | 330% | - | -33.2% | 9.35% | -16.6% | -1.92% | 0.01% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.6 | 1.23 | -0.48 | -0.58 | 0.03 | -1.72 | 0.1901 | 0.1506 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 7.758 | 85.58 | 26.57 | 38.18 | 70.94 | 71.12 | 95.2 | 119.3 |
| EBITDA 1 | -74.03 | 34.56 | -25.46 | -24.93 | 5.005 | -51.79 | 28.08 | 60.67 |
| EBIT 1 | -77.59 | 31.82 | -27.29 | -26.58 | 3.281 | -4.5 | 29.22 | 61 |
| Net income 1 | -101.2 | 67.26 | -23.72 | -28.89 | 1.507 | -85.97 | 18.63 | 0.0333 |
| Net Debt 1 | 14.66 | -184.5 | -65.28 | -7.611 | -19.66 | -95.52 | -46.87 | -56.87 |
| Reference price 2 | 3.99 | 4.32 | 3.97 | 3.54 | 3.54 | 13.40 | 13.40 | 13.40 |
| Nbr of stocks (in thousands) | 38,811 | 49,727 | 49,655 | 49,712 | 49,865 | 50,024 | 50,024 | - |
| Announcement Date | 4/1/21 | 4/7/22 | 4/13/23 | 4/4/24 | 4/24/25 | 4/2/26 | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 34.6x | 6.07x | 18.79x | 0.95% | 49.92B | ||
| -23.69x | 348.89x | -22.4x | -.--% | 40.23B | ||
| 25.19x | 2.79x | 12.06x | -.--% | 34.55B | ||
| 44.97x | 4.49x | 28.67x | -.--% | 33.09B | ||
| 30.52x | 8.33x | 21.46x | 0.41% | 27.51B | ||
| 32.72x | 5.32x | 24.23x | -.--% | 15.92B | ||
| 24.09x | 2.05x | 9x | 1.11% | 13.86B | ||
| -22.69x | 14.88x | -22.26x | -.--% | 13.52B | ||
| Average | 18.21x | 49.10x | 8.69x | 0.31% | 28.58B | |
| Weighted average by Cap. | 19.77x | 66.17x | 9.63x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GNFT Stock
- XUP Stock
- Valuation GENFIT
Select your edition
All financial news and data tailored to specific country editions
















